Who are oseltamivir and chinese medicinal herbs's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oseltamivir-and-chinese-medicinal-herbs.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

oseltamivir and chinese medicinal herbs — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

oseltamivir and chinese medicinal herbs (oseltamivir and chinese medicinal herbs) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor combined with herbal supplement. Area: Infectious Disease / Virology.

marketed Neuraminidase inhibitor combined with herbal supplement Influenza viral neuraminidase; herbal targets unknown Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

oseltamivir and chinese medicinal herbs (oseltamivir and chinese medicinal herbs) — Capital Medical University. Oseltamivir inhibits viral neuraminidase to prevent influenza virus release, while Chinese medicinal herbs provide adjunctive immunomodulatory and anti-inflammatory support.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oseltamivir and chinese medicinal herbs TARGET	oseltamivir and chinese medicinal herbs	Capital Medical University	marketed	Neuraminidase inhibitor combined with herbal supplement	Influenza viral neuraminidase; herbal targets unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor combined with herbal supplement class)

Capital Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oseltamivir and chinese medicinal herbs — Competitive Intelligence Brief. https://druglandscape.com/ci/oseltamivir-and-chinese-medicinal-herbs. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab